These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34873819)

  • 1. Adults with Down syndrome in randomized clinical trials targeting prevention of Alzheimer's disease.
    Silverman W; Krinsky-McHale SJ; Zigman WB; Schupf N;
    Alzheimers Dement; 2022 Oct; 18(10):1736-1743. PubMed ID: 34873819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
    Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
    Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personality and behaviour changes mark the early stages of Alzheimer's disease in adults with Down's syndrome: findings from a prospective population-based study.
    Ball SL; Holland AJ; Hon J; Huppert FA; Treppner P; Watson PC
    Int J Geriatr Psychiatry; 2006 Jul; 21(7):661-73. PubMed ID: 16802281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome.
    Startin CM; Hamburg S; Hithersay R; Al-Janabi T; Mok KY; Hardy J; ; Strydom A
    Alzheimers Dement; 2019 Feb; 15(2):245-257. PubMed ID: 30503169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome.
    Hithersay R; Baksh RA; Startin CM; Wijeratne P; Hamburg S; Carter B; ; Strydom A
    Alzheimers Dement; 2021 Apr; 17(4):595-604. PubMed ID: 33226718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome.
    Videla L; Benejam B; Pegueroles J; Carmona-Iragui M; Padilla C; Fernández S; Barroeta I; Altuna M; Valldeneu S; Garzón D; Ribas L; Montal V; Arranz Martínez J; Rozalem Aranha M; Alcolea D; Bejanin A; Iulita MF; Videla Cés S; Blesa R; Lleó A; Fortea J
    JAMA Netw Open; 2022 Aug; 5(8):e2225573. PubMed ID: 35930282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid age and tau PET timeline to symptomatic Alzheimer's disease in Down syndrome.
    Schworer EK; Zammit MD; Wang J; Handen BL; Betthauser T; Laymon CM; Tudorascu DL; Cohen AD; Zaman SH; Ances BM; Mapstone M; Head E; Klunk WE; Christian BT; Hartley SL;
    medRxiv; 2024 Aug; ():. PubMed ID: 39211859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective attention deficits associated with mild cognitive impairment and early stage Alzheimer's disease in adults with Down syndrome.
    Krinsky-McHale SJ; Devenny DA; Kittler P; Silverman W
    Am J Ment Retard; 2008 Sep; 113(5):369-86. PubMed ID: 18702557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MGEKN; Tabet N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial.
    Cooper SA; Caslake M; Evans J; Hassiotis A; Jahoda A; McConnachie A; Morrison J; Ring H; Starr J; Stiles C; Sullivan F
    Trials; 2014 Jun; 15():202. PubMed ID: 24888381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a smartphone screening test for preclinical Alzheimer's disease and validation across the dementia continuum.
    Alty J; Goldberg LR; Roccati E; Lawler K; Bai Q; Huang G; Bindoff AD; Li R; Wang X; St George RJ; Rudd K; Bartlett L; Collins JM; Aiyede M; Fernando N; Bhagwat A; Giffard J; Salmon K; McDonald S; King AE; Vickers JC
    BMC Neurol; 2024 Apr; 24(1):127. PubMed ID: 38627686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial.
    Cooper SA; Ademola T; Caslake M; Douglas E; Evans J; Greenlaw N; Haig C; Hassiotis A; Jahoda A; McConnachie A; Morrison J; Ring H; Starr J; Stiles C; Sirisena C; Sullivan F
    Trials; 2016 Jul; 17():370. PubMed ID: 27473843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
    Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
    J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prodromal Alzheimer's disease can affect activities of daily living for adults with Down syndrome.
    Listwan TA; Krinsky-McHale SJ; Kovacs CM; Lee JH; Pang DI; Schupf N; Tycko B; Zigman WB; Silverman W
    Alzheimers Dement (Amst); 2024; 16(1):e12562. PubMed ID: 38476636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.
    Carmona-Iragui M; Alcolea D; Barroeta I; Videla L; Muñoz L; Van Pelt KL; Schmitt FA; Lightner DD; Koehl LM; Jicha G; Sacco S; Mircher C; Pape SE; Hithersay R; Clare ICH; Holland AJ; Nübling G; Levin J; Zaman SH; Strydom A; Rebillat AS; Head E; Blesa R; Lleó A; Fortea J
    Lancet Neurol; 2021 Aug; 20(8):605-614. PubMed ID: 34302785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study.
    Montoliu-Gaya L; Alcolea D; Ashton NJ; Pegueroles J; Levin J; Bosch B; Lantero-Rodriguez J; Carmona-Iragui M; Wagemann O; Balasa M; Kac PR; Barroeta I; Lladó A; Brum WS; Videla L; Gonzalez-Ortiz F; Benejam B; Arranz Martínez JJ; Karikari TK; Nübling G; Bejanin A; Benedet AL; Blesa R; Lleó A; Blennow K; Sánchez-Valle R; Zetterberg H; Fortea J
    EBioMedicine; 2023 Apr; 90():104547. PubMed ID: 37002988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.